Ro-3306

Catalog No.S7747

Molecular Weight(MW): 351.45

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Cited by 22 Publications

Nature, 2016, 539(7627):54-58

PubMed: 27760120 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Nucleic Acids Res, 2019, 10.1093/nar/gkz602

PubMed: 31291454 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 10.1073/pnas.1915108116

PubMed: 31712441 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(27):13374-13383

PubMed: 31209037 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472.CAN-18-2486

PubMed: 31253668 ( click the link to review the publication )

Cancer Res, 2019, 10.1158/0008-5472

PubMed: 31484670 ( click the link to review the publication )

J Virol, 2019, 93(14)

PubMed: 31043526 ( click the link to review the publication )

Mol Cell, 2019, 10.1016/j.molcel.2019.10.016

PubMed: 31733992 ( click the link to review the publication )

Cancers (Basel), 2019, 11(11)

PubMed: 31703356 ( click the link to review the publication )

FEBS Lett, 2018, 592(11):1893-1904

PubMed: 29782647 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(12)

PubMed: 30545129 ( click the link to review the publication )

Cancer research, 2018, 10.1158/0008-5472.CAN-17-2288

PubMed: ( click the link to review the publication )

FASEB J, 2018, 10.1096/fj.201801369R

PubMed: 30496702 ( click the link to review the publication )

Mol Cell Biol, 2017, 37(20)

PubMed: 28760773 ( click the link to review the publication )

Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Oncotarget, 2017, 8(53):90662-90673

PubMed: 29207595 ( click the link to review the publication )

Sci Rep, 2017, 7:41950

PubMed: 28176818 ( click the link to review the publication )

Arthritis Rheumatol , 2016, 68(5):1222-32

PubMed: 26663909 ( click the link to review the publication )

Cell Cycle, 2016, 15(20):2742-52

PubMed: 27580187 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0149099

PubMed: 26881434 ( click the link to review the publication )

J Cell Biol, 2015, 209(2):221-34

PubMed: 25918224 ( click the link to review the publication )

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

Targets

CDK1 ^[1] (Cell-free assay)	PKCδ ^[1] (Cell-free assay)	SGK ^[1] (Cell-free assay)	ERK ^[1] (Cell-free assay)
20 nM(Ki)	318 nM(Ki)	497 nM(Ki)	1980 nM(Ki)

In vitro

RO-3306 inhibits CDK1/cyclin B1, CDK1/cyclin A, CDK2/cyclin E, and CDK4/cyclin D activity with Ki of 35 nM, 110 nM, 340 nM, and over 2000 nM, respectively. Treatment of HCT116, SW480, and HeLa cells with RO-3306 for 20 h leads to a complete block of the cell cycle in the G2/M phase. The proliferation of both HCT116 and SW480 is effectively blocked by RO-3306. RO-3306 appears to be more proapoptotic in cancer cells (HCT116 and SW480) than nontumorigenic cells (MCF 10A and MCF 12A).^[1] RO-3306 effectively arrests oocyte maturation at a concentration of 10 μM.^[2]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
human NCI-SNU-1 cell	MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHfuTm5KdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRTBwN{OwPVUh\|ryP	Mny4V2FPT0WU
human H460a cells	M1\6eXBzd2yrZnXyZZRqd25iYYPzZZk>		NFzIcZVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlBiKGOnbHzzMEBKSzVyPUGuNFQh\|ryP	NWTFV3J1OTd\|MEO0NlE>
human MDA435 cells	MlPSVJJwdGmoZYLheIlwdiCjc4PhfS=>		M174XmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBOFM2KGOnbHzzMEBKSzVyPUGuNVQh\|ryP	NUXFO\|MxOTd\|MEO0NlE>
human HCT116 cells	MXLQdo9tcW[ncnH0bY9vKGG\|c3H5		Mkn6RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ2SxNVYh[2WubIOsJGlEPTB;MT6xOEDPxE1?	M1\xPVE4OzB\|NEKx
human H4 cell	M2HXemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVrJcohq[mm2aX;uJI9nKGi3bXHuJGg1KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OS5zNUi3OUDPxE1?	NXSwO4NzW0GQR1XS
human PA-1 cell	NUSzVVRST3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NV3se2pSUW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4zOjZ3NDFOwG0>	MnzJV2FPT0WU
human T98G cell	M3LGNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NVfiUpM{UW6qaXLpeIlwdiCxZjDoeY1idiCWOUjHJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU4{PjhzMjFOwG0>	NUfDTGtJW0GQR1XS
human SW1710 cell	NHGybHlIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NYTvWWFmUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yNjZzNEC4JO69VQ>?	M1G5R3NCVkeHUh?=
human U251 cell	NYTDXlZWT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MoCxTY5pcWKrdHnvckBw\iCqdX3hckBWOjVzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MT62N\|c4OSEQvF2=	NXfE[Zp3W0GQR1XS
human ALL-PO cell	MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MXPJcohq[mm2aX;uJI9nKGi3bXHuJGFNVC2STzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H589yNKEmFNUC9NU46ODhzMzFOwG0>	M2C2NnNCVkeHUh?=
human RKO cells	NGq1eJRRem:uaX\ldoF1cW:wIHHzd4F6		NXXNWpJNSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDST28h[2WubIOsJGlEPTB;MjFOwG0>	MXKxO\|MxOzR{MR?=
human SK-N-DZ cell	NF;QXXBIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M33IdGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTj3EXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvODF6N{[g{txO	NEjUR3lUSU6JRWK=
human A4-Fuk cell	NXG5d5gzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		Ml[0TY5pcWKrdHnvckBw\iCqdX3hckBCPC2IdXugZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA2PjB2IN88US=>	NXrHcmRMW0GQR1XS
human SW480 cells	NXXKT2VWWHKxbHnm[ZJifGmxbjDhd5NigQ>?		NVPtfGZ6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTW\|Q5OCClZXzsd{whUUN3ME2yMlIh\|ryP	NYHQd\|ZkOTd\|MEO0NlE>
human 639-V cell	Ml;5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{Ly[mlvcGmkaYTpc44hd2ZiaIXtZY4hPjN7LW[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlI4PTN5IN88US=>	NV3vXHE3W0GQR1XS
human Hs-578-T cell	M1;sZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NIjqT5lKdmirYnn0bY9vKG:oIHj1cYFvKEi\|LUW3PE1VKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Oi5{N{e5PUDPxE1?	M{DYR3NCVkeHUh?=
human UM-UC-3 cell	MnXsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M2DySmlvcGmkaYTpc44hd2ZiaIXtZY4hXU1vVVOtN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:Oi55M{mzOkDPxE1?	M3fYcnNCVkeHUh?=
human BPH-1 cell	NY[0RnZwT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NXLxfWw2UW6qaXLpeIlwdiCxZjDoeY1idiCEUFitNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQTd2NUWg{txO	NFvxe5BUSU6JRWK=
human 5637 cell	MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1\N[GlvcGmkaYTpc44hd2ZiaIXtZY4hPTZ\|NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUOuNFg2OzJizszN	Mle1V2FPT0WU
human 8-MG-BA cell	NXLTfHNOT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3vzNWlvcGmkaYTpc44hd2ZiaIXtZY4hQC2PRz3CRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F697zOIFnDOVA:Oy5zNEC0PUDPxE1?	MYXTRW5ITVJ?
human HCT116 cells	MXLDfZRwfG:6aXRCpIF{e2G7	MUC1JIRigXN?	NHvMO\|hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1RzMU[gZ4VtdHNiYX\0[ZIhPSCmYYnzJIJ6KE2WUzDhd5Nige,:jDDJR\|UxRTNwMjFOwG0>	NUi0OnRmOjJ\|Mk[xOlg>
human LB1047-RCC cell	M4XuO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MVTJcohq[mm2aX;uJI9nKGi3bXHuJGxDOTB2Nz3SR2Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjJ\|NUCxJO69VQ>?	MYnTRW5ITVJ?
human KOSC-2 cell	MorFS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MofZTY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ1PjZ4MjFOwG0>	MkDKV2FPT0WU
human COR-L88 cell	NVHmRmR2T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M13EOWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:ULVy4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPDd3OEOg{txO	NX3oTYw1W0GQR1XS
human PSN1 cell	MXrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MlznTY5pcWKrdHnvckBw\iCqdX3hckBRW05zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6xNFgxPSEQvF2=	M4DIdnNCVkeHUh?=
human LXF-289 cell	NW[4PW9FT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGxZTi1{OEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlIyPzZizszN	MkX6V2FPT0WU
human MN-60 cell	MWjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MW\Jcohq[mm2aX;uJI9nKGi3bXHuJG1PNTZyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND6zO\|YzOyEQvF2=	NF7YPI1USU6JRWK=
human NEC8 cell	NVG0UIJ5T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYWyTVFzUW6qaXLpeIlwdiCxZjDoeY1idiCQRVO4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE41PzB5NjFOwG0>	MX;TRW5ITVJ?
human SJSA1 cells	NHXsSI9Rem:uaX\ldoF1cW:wIHHzd4F6		M2LYfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1rTRVEh[2WubIOsJGlEPTB;ND61OUDPxE1?	M3TyRVE4OzB\|NEKx
human NCI-H2405 cell	NYHV[3dZT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MnXnTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEK0NFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njd2NEmzJO69VQ>?	M3vSfXNCVkeHUh?=
human YH-13 cell	NX;sNI5yT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVjJcohq[mm2aX;uJI9nKGi3bXHuJHlJNTF\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;ND63OVc4PiEQvF2=	MojyV2FPT0WU
human SK-MEL-2 cell	NEfMXopIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MYPJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU2HTD2yJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4xQTZ\|MjFOoI0>	M2TNOnNCVkeHUh?=
human NB13 cell	NEf6RWVIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2LITWlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|I4QDZizszN	MoH2V2FPT0WU
human GAMG cell	Mo\BS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4LiRmlvcGmkaYTpc44hd2ZiaIXtZY4hT0GPRzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuN\|cyPSEQvF2=	M2D0[HNCVkeHUh?=
human NCI-H1792 cell	MkjPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M{XzbGlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixO\|kzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS52N{m1OEDPxE1?	NFvTdHpUSU6JRWK=
human KP-4 cell	Mln2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MoTsTY5pcWKrdHnvckBw\iCqdX3hckBMWC12IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;NT62PVgzOyEQvF2=	NYLrepF7W0GQR1XS
human HGC-27 cell	NVHTZ2hLT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NEfPTY1KdmirYnn0bY9vKG:oIHj1cYFvKEiJQz2yO{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvPzNyN{eg{txO	M1L5OHNCVkeHUh?=
human GCT cell	NHy2SJhIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NXfzVJJtUW6qaXLpeIlwdiCxZjDoeY1idiCJQ2SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlg2OTJzIN88US=>	NHvtUmFUSU6JRWK=
human PFSK-1 cell	NYWwfpE6T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MWfJcohq[mm2aX;uJI9nKGi3bXHuJHBHW0tvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPFYyPjhizszN	NHzuUGhUSU6JRWK=
human A172 cell	MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M4DXXGlvcGmkaYTpc44hd2ZiaIXtZY4hSTF5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUWuPVA4QSEQvF2=	Moi0V2FPT0WU
human HO-1-N-1 cell	M4rSWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		MV\Jcohq[mm2aX;uJI9nKGi3bXHuJGhQNTFvTj2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU46PTR{NTFOwG0>	MUXTRW5ITVJ?
human HN cell	NWrIXYVJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		M3zXTmlvcGmkaYTpc44hd2ZiaIXtZY4hUE5iY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lkm3NFk4KM7:TR?=	NHnES5JUSU6JRWK=
human IST-MES1 cell	M3TqXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M{TV[mlvcGmkaYTpc44hd2ZiaIXtZY4hUVOWLV3FV\|Eh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02Njl5NUKxJO69VQ>?	MmGxV2FPT0WU
human TGW cell	M{H3Xmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NITW[VNKdmirYnn0bY9vKG:oIHj1cYFvKFSJVzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPU[uNFU3QDJizszN	NEDEOVRUSU6JRWK=
human COR-L23 cell	MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NH\i[IlKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNlMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjN5M{Wg{txO	M3TnWnNCVkeHUh?=
human D-566MG cell	M{W0W2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NHezRWNKdmirYnn0bY9vKG:oIHj1cYFvKERvNU[2UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03Njd6OEezJO69VQ>?	MVTTRW5ITVJ?
human SKG-IIIa cell	NIDPS2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M4XkeGlvcGmkaYTpc44hd2ZiaIXtZY4hW0uJLVnJTYEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03Njh3NUeyJO69VQ>?	NGLGOFFUSU6JRWK=
human NCI-H446 cell	MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGnFOIFKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOFQ3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Py5yMUixJO69VQ>?	NG\nSIRUSU6JRWK=
human KYSE-270 cell	MkLOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		Moi5TY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUK3NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvODN6N{Kg{txO	NILmWZhUSU6JRWK=
human CAL-39 cell	NVLkcIpUT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NHTWNWZKdmirYnn0bY9vKG:oIHj1cYFvKEODTD2zPUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzV{NDFOwG0>	MWjTRW5ITVJ?
human IST-SL1 cell	MnfNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MnfWTY5pcWKrdHnvckBw\iCqdX3hckBKW1RvU1yxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9O{41OzN2OTFOwG0>	MXPTRW5ITVJ?
human SF539 cell	MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M17iXmlvcGmkaYTpc44hd2ZiaIXtZY4hW0Z3M{mgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME23MlU2OTl5IN88US=>	M1HodnNCVkeHUh?=
human TE-1 cell	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M1XIRWlvcGmkaYTpc44hd2ZiaIXtZY4hXEVvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuPFkxQTFizszN	MlnHV2FPT0WU
human NB10 cell	NVHBfW1oT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYDJcohq[mm2aX;uJI9nKGi3bXHuJG5DOTBiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD15Lkm4O\|U5KM7:TR?=	MkL6V2FPT0WU
human 8505C cell	NXe3TI5WT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlvWTY5pcWKrdHnvckBw\iCqdX3hckA5PTB3QzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyPUeuPVk5OTdizszN	M37ubHNCVkeHUh?=
human DB cell	M4LYNWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Ml;JTY5pcWKrdHnvckBw\iCqdX3hckBFSiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxRThwMEGxN\|Eh\|ryP	NXXDOoFrW0GQR1XS
human NCI-H28 cell	M4S0WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		NXu3cnY1UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI5KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:QC53OUi4OEDPxE1?	MlTqV2FPT0WU
human LOXIMVI cell	MmLjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYLJcohq[mm2aX;uJI9nKGi3bXHuJGxQYEmPVlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlY{PzBzIN88US=>	M{PtOnNCVkeHUh?=
human ME-180 cell	NVfNXmYzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlzpTY5pcWKrdHnvckBw\iCqdX3hckBOTS1zOECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24MlgxOzl3IN88US=>	NEjHTYJUSU6JRWK=
human ES3 cell	MoHOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NUS2OWZTUW6qaXLpeIlwdiCxZjDoeY1idiCHU{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlEzPzl2IN88US=>	MoDSV2FPT0WU
human SK-N-FI cell	NEHmTWJIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVfJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU5vRlmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME25MlQyPjl7IN88US=>	NHr6TXVUSU6JRWK=
human NBsusSR cell	NF7Ce3NIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		NFn3fpFKdmirYnn0bY9vKG:oIHj1cYFvKE6Ec4XzV3Ih[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOC5{M{G4JO69VQ>?	M1rUU3NCVkeHUh?=
human MCF7 cell	MWDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NHO3WZNKdmirYnn0bY9vKG:oIHj1cYFvKE2FRkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU4yQDR7IN88US=>	NHz0[lBUSU6JRWK=
human A549 cell	NWDSclQ3T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NE[3bplKdmirYnn0bY9vKG:oIHj1cYFvKEF3NEmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNU4zODZizszN	MWXTRW5ITVJ?
human HuP-T4 cell	MmiyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		M4PyUWlvcGmkaYTpc44hd2ZiaIXtZY4hUHWSLWS0JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAvPDJ5MTFOwG0>	MX\TRW5ITVJ?
human HSC-2 cell	NXnx[2VRT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MVLJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUGsO\|g1OiEQvF2=	MkO2V2FPT0WU
human A253 cell	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NYKzS5Y6UW6qaXLpeIlwdiCxZjDoeY1idiCDMkWzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVUvOjh\|NDFOwG0>	M{jrV3NCVkeHUh?=
human HCT-116 cell	NGTyU\|ZIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MkjjTY5pcWKrdHnvckBw\iCqdX3hckBRSy1\|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTB;MUiuNFA1OyEQvF2=	MY\TRW5ITVJ?
human HCT-116 cell	NEHF[Y1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?=		MVvJcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xPU43PjhizszN	NVTWXFJvW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Cdk1 / Cdk1 / Cleaved PARP / Cleaved caspase-3 / p-p38 / Bad / Apaf1-1 / p-H2Ax / Bim / Bad; PubMed: 27385216 Oncotarget OVCA-429 and OVCAR-3 were exposed to RO-3306 for 24 h in indicated dose dependent manner, (F) 10 uM RO-3306 for 12 h up to 48 h. The expression level of the indicated protein and the phosphorylated form of H2A.x and p38 were examined via Western blot analyses.	27385216
Immunofluorescence	PARP1 / Plk1 ; PubMed: 28069876 Mol Cancer Ther Representative images of IF staining for PARP1 and Plk1 in 22RV1 cells treated with 0.3 mM mimosine for 20 h, 4 mM hydroxyurea for 24 h, 10 µM RO-3306 for 7 h or 200 ng/ml nocodazole (Noc) for 12 h.	28069876
Growth inhibition assay	Cell viability; PubMed: 27385216 Oncotarget OVCA-429 and OVCAR-3 were exposed to RO-3306 in indicated time- and dose-dependent manner. Cell viability were measured via crystal violet assay. Results are the means ± S.E. n = 3.	27385216

Protocol

Kinase Assay:^[1]	- Collapse CDK assay: The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.
Cell Research:^[3]	- Collapse Cell lines: MDA-MB-231 cell line Concentrations: 20 μM Incubation Time: 72 h Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength. (Only for Reference)

Kinase Assay:^[1]

- Collapse

CDK assay:

The activity of CDK1 cyclin B1, CDK1 cyclin A, CDK2 cyclin E, and CDK4 cyclin D is measured by a homogeneous time-resolved fluorescence assay in a 96-well format. The assay buffer contained 25 mM Hepes, 6.25 mM MgCl2, 0.003% Tween 20, 0.3 mg/mL BSA, 1.5 mM DTT, and ATP as follows: 162 μM (CDK1), 90 mM (CDK2), or 135 μM (CDK4). CDK1 and CDK2 buffer contained 10 mM MgCl2. Test compounds are diluted in assay buffer to 3-fold their final concentration in 20 μL, and the reaction is started by the addition of a 40 μL assay buffer containing the pRB substrate (0.185μM). The plates are incubated at 37°C for 30 min with constant agitation, and the reaction is terminated by the addition of 15 μL of 1.6μM anti-phospho pRB antibody (Ser-780) in 25 mM Hepes, 24 mM EDTA, and 0.2 mg/mL BSA. After an additional 30 min of incubation with shaking, 15μL of 3nM Lance-Eu-W1024-labeledanti-rabbitIgG and 60 nM Alophycocyanin-conjugated anti-His-6 antibody in 25 mM Hepes, and 0.5 mg/mL BSA is added and incubated for 1 h. The plates are read in the Victor-V multi- label reader at excitation 340 nm and emission 615 nm and 665 nm. The IC50 values are calculated from the readings at 665 nm and normalized for Europium readings at 615 nm. Ki values are calculated according to the equation: Ki= IC50/(1 + S/Km ), where S is the ATP concentration in the assay and Km is the Michaelis-Menten constant for ATP. The inhibitory activity against the panel of kinases is determined by the IMAP assay technology.

Cell Research:^[3]

- Collapse

Cell lines: MDA-MB-231 cell line
Concentrations: 20 μM
Incubation Time: 72 h
Method: Log phases cells (25,000) are seeed in 96-well plates and incubated in a 37℃ incubator with CO2, After 24 h, different concentrations of RO-3306 are administered to determine the drug concentrations required to achieve a 50% growth inhibition (IC50). MTT (20 μL, 5mg/mL stock solution in saline) is added to each well and the cells are incubated for 4 h. Supernatants are removed and formazan crystals from viable cells are solubilized with 200 μL anhydrous DMSO. The absorbance is detected with a 550 model microplate reader at the 565 nm wavelength.
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	13 mg/mL warmed (36.98 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Ro-3306 SDF

Molecular Weight	351.45
Formula	C₁₈H₁₃N₃OS₂
CAS No.	872573-93-8
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

CDK Signaling Pathway Map

Related CDK Products

SU9516 ^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Purvalanol A ^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.
AT7519 HCl ^New

AT7519 HCl is a multi-CDK inhibitor for CDK1, 2, 4, 6 and 9 with IC50 of 10-210 nM in cell-free assays. It is less potent to CDK3 and little active to CDK7. Phase 2.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.
Flavopiridol HCl

Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.
Roscovitine (Seliciclib,CYC202)

Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
abemaciclib mesylate (LY2835219)

abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306

Cited by 22 Publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ro-3306 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

CDK Signaling Pathway Map

Related CDK Products

Choose Your Country or Region

By Signaling Pathways

By product type

Ro-3306

Cited by 22 Publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Ro-3306 SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

CDK Signaling Pathway Map

Related CDK Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)